1
|
Jiménez-Fonseca P, Sastre J, García-Alfonso P, Gómez-España MA, Salud A, Gil S, Rivera F, Reina JJ, Quintero G, Valladares-Ayerbes M, Safont MJ, La Casta A, Robles-Díaz L, García-Paredes B, López López R, Guillot M, Gallego J, Alonso-Orduña V, Diaz-Rubio E, Aranda E. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials. Clin Colorectal Cancer 2023; 22:222-230. [PMID: 36944559 DOI: 10.1016/j.clcc.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 01/30/2023] [Accepted: 02/10/2023] [Indexed: 02/25/2023]
Abstract
BACKGROUND The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs. <3) in previously untreated mCRC. PATIENTS AND METHODS The study involved 589 untreated mCRC patients included in the intention-to-treat population of 2 randomized clinical trials (phase III VISNU-1 [NCT01640405] and phase II VISNU-2 [NCT01640444] studies). RESULTS Of the 589 patients, 349 (59.2%) had bCTC≥3 and 240 (40.7%) had bCTC<3. Multivariate analysis showed that the bCTC count is an independent prognostic factor for overall survival (OS) (HR 0.59, 95% CI 0.48-0.72; P = 0.000) and potential for progression-free survival (PFS) (P = 0.0549). Median OS was 32.9 and 19.5 months in patients with bCTC<3 and bCTC≥3 (P <0.001), respectively. This effect was also observed comparing OS in RASwt patients from both studies. Other prognostic factors were: ECOG-PS, primary tumor site, number of metastatic sites and surgery of the primary tumor. Median OS was lower for patients treated with anti-VEGF versus anti-EGFR (22.3 vs. 33.3 months, P <0.0001) while there were no significant differences in PFS according to the targeted treatment received. CONCLUSION This post-hoc analysis of 2 randomized studies confirms the poor prognosis of patients with bCTC≥3 but this is not associated with other adverse independent prognostic factors such as RAS/BRAF mutations.
Collapse
Affiliation(s)
- P Jiménez-Fonseca
- Department of Medical Oncology. Hospital Universitario Central de Asturias, ISPA, Oviedo, 33011, Spain.
| | - J Sastre
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - P García-Alfonso
- Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, 28007, Spain
| | - M A Gómez-España
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | - A Salud
- Department of Medical Oncology, Hospital Universitario Arnau de Vilanova, Lérida, 25198, Spain
| | - S Gil
- Department of Medical Oncology. Hospital Universitario Regional y Virgen de la Victoria, IBIMA, Málaga, 29010, Spain
| | - F Rivera
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, 39008, Spain
| | - J J Reina
- Department of Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Sevilla, 41009, Spain
| | - G Quintero
- Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, 27003, Spain
| | - M Valladares-Ayerbes
- Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain
| | - M J Safont
- Department of Medical Oncology, Hospital General Universitario de Valencia, CIBERONC, Universidad de Valencia, Valencia, 46014, Spain
| | - A La Casta
- Department of Medical Oncology, Hospital de Donostia, Guipúzcoa, 20014, Spain
| | - L Robles-Díaz
- Department of Medical Oncology. Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
| | - B García-Paredes
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - R López López
- Department of Medical Oncology and Translational Medical Oncology Group. Hospital Universitario Santiago de Compostela and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela, 15706, Spain
| | - M Guillot
- Department of Medical Oncology. Hospital Universitario Son Espases, Palma de Mallorca, 07120, Spain
| | - J Gallego
- Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, 03203, Spain
| | - V Alonso-Orduña
- Department of Medical Oncology, Hospital Universitario Miguel Servet. Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, 50009, Spain
| | - E Diaz-Rubio
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - E Aranda
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | | |
Collapse
|
2
|
Cho E, Kim JY, Cho B, Lee JS, Yoon YC, Shin YC, Kim H, Gil S, Kim S. Efficacy of fermented grain using Bacillus coagulans in reducing visceral fat among people with obesity: a randomized controlled trial. Front Nutr 2023; 10:1148512. [PMID: 37139448 PMCID: PMC10149940 DOI: 10.3389/fnut.2023.1148512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 04/03/2023] [Indexed: 05/05/2023] Open
Abstract
Background Obesity is a socioeconomic problem, and visceral obesity, in particular, is related to cardiovascular diseases or metabolic syndrome. Fermented grains and various microorganisms are known to help with anti-obesity effects and weight management. Studies on the relationship between Bacillus coagulans and anti-obesity effects are not well known, and studies on the application of fermented grains and microorganisms to the human body are also insufficient. Objectives This study aimed to evaluate the efficacy of Curezyme-LAC, an ingredient mixed with six-grain types fermented by B. coagulans, in reducing fat mass in adults with obesity. Methods In this randomized double-blinded placebo-controlled study, 100 participants [aged 40-65 years; body mass index (BMI) ≥ 25 to ≤ 33 kg/m2) were randomly allocated to two groups: 4 g/day Curezyme-LAC administered as a granulated powder or placebo (steamed grain powder mixture). Results After 12 weeks, visceral adipose tissue decreased significantly in the Curezyme-LAC group compared with that in the placebo group (mean ± standard error, SE of -9.3 cm2 ± 5.1) vs. (6.8 cm2 ± 3.4; p = 0.008). Compared to the placebo group, the Curezyme-LAC group also showed significant reductions in total fat mass (-0.43 ± 0.24 kg vs. 0.31 ± 0.19 kg, p = 0.011), body weight (-0.4 ± 0.3 kg vs. 0.3 ± 0.2 kg, p = 0.021), BMI (-0.14 ± 0.12 vs. 0.10 ± 0.07, p = 0.028), and waist circumference (-0.6 ± 0.2 cm vs. -0.1 ± 0.2 cm, p = 0.018) without a change in dietary intake and physical activity. Conclusion Curezyme-LAC supplementation for 12 weeks may benefit individuals with obesity by reducing visceral fat mass.
Collapse
Affiliation(s)
- Eunbyul Cho
- Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
| | - Ju Young Kim
- Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
- *Correspondence: Ju Young Kim,
| | - Belong Cho
- Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
- Belong Cho,
| | | | | | | | - Hyerim Kim
- Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
| | - Siye Gil
- Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
| | - Sohye Kim
- Nutrition Care Services, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
| |
Collapse
|
3
|
Gutierrez E, Carrion I, Olmos C, Jimenez P, Nombela L, Pozo E, Mahia P, Gil S, De Agustin A, Islas F. Cardiac damage staging in patients undergoing TAVR. Incremental value of global longitudinal strain and right ventricular-arterial coupling. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Transcatheter aortic valve replacement (TAVR) is nowadays a safe and increasingly frequent option to treat severe aortic stenosis (AS). Cardiac damage staging has been proposed and validated in some studies as a prognostic tool; however, many patients continue to undergo aortic valve replacement only after there is evidence of cardiac damage. The aim of this study is to assess the potential incremental value of global longitudinal strain (GLS) and right ventricular-arterial coupling (RV-VAc) in the prognostic performance of the cardiac damage staging.
Methods
Consecutive patients with AS and undergoing TAVR were included in our hospital registry. Baseline echocardiography was performed before TAVR according to current guidelines. For this study, patients were classified based on the following stage of cardiac damage: Stage 0: no cardiac damage; Stage 1: left ventricular (LV) damage (LV ejection fraction (LVEF) <50%, LV mass index >95 g/m2 for women, >115 g/m2 for men); Stage 2: left atrial (LA) or mitral valve damage (LA volume index >34 ml/m2, mitral regurgitation moderate-severe, or presence of atrial fibrillation); Stage 3: pulmonary vasculature or tricuspid valve damage (systolic pulmonary artery pressure 60 mmHg, or tricuspid regurgitation moderate-severe); Stage 4: RV damage (TAPSE <1.7 cm, S' <9.5 cm/s).
Results
496 patients were studied. Mean age of the cohort was 81.9±6.2 years, mean aortic valve area was 0.86±0.6 cm2, mean LVEF was 57.9±12.3%, mean LV-GLS was −15.6±3.5% and RV-Vac was 0.61±0.34. Table 1 shows clinical and echo characteristics of patients. Only one patient (0.2%) met criteria for stage 0; 38 (7.7%) patients were in stage 1; 159 (32.1%) patients in stage 2, 157 (31.7%) patients in stage 3 and 141 (28.4%) patients in stage 4. 1-year mortality for stage 1 was (10.5%), for stage 2 (13.7%), for stage 3 (32.2%) and for stage 4 (19.5%). The area under the ROC curve (AUC) for 1-year mortality for the cardiac damage staging system was 0.622, CI (0.539–0.705); the best cut-off value for LV-GLS to predict 1-year mortality was −14% with an AUC of 0.634 CI (0.487–0.781) and RV-VAc had an AUC of 0.748 CI (0.638–858). Finally, the model that included the staging system, LV-GLS and RV-VAc had an AUC ROC of 0.875, CI (0.780–0.971) (Figure 1).
Conclusions
Cardiac damage staging is a good prognostic tool and it has been validated in several studies, however, the addition of feasible and widely available echo parameters such as LV-GLS and RV-VAc can significantly increase its prognostic yield.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- E Gutierrez
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - I Carrion
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - C Olmos
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - P Jimenez
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - L Nombela
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - E Pozo
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - P Mahia
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - S Gil
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - A De Agustin
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - F Islas
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| |
Collapse
|
4
|
Alcazar M, Escribano J, Ferré N, Closa-Monasterolo R, Selma-Royo M, Feliu A, Castillejo G, Luque V, Closa-Monasterolo R, Escribano J, Luque V, Feliu-Rovira A, Ferré N, Muñoz-Hernando J, Gutiérrez-Marín D, Zaragoza-Jordana M, Gispert-Llauradó M, Rubio-Torrents M, Núñez-Roig M, Alcázar M, Sentís S, Esteve M, Monné-Gelonch R, Basora J, Flores G, Hsu P, Rey-Reñones C, Alegret C, Guillen N, Alegret-Basora C, Ferre R, Arasa F, Alejos A, Diéguez M, Serrano M, Mallafré M, González-Hidalgo R, Braviz L, Resa A, Palacios M, Sabaté A, Simón L, Losilla A, De La Torre S, Rosell L, Adell N, Pérez C, Tudela-Valls C, Caro-Garduño R, Salvadó O, Pedraza A, Conchillo J, Morillo S, Garcia S, Mur E, Paixà S, Tolós S, Martín R, Aguado F, Cabedo J, Quezada L, Domingo M, Ortega M, Garcia R, Romero O, Pérez M, Fernández M, Villalobos M, Ricomà G, Capell E, Bosch M, Donado A, Sanchis F, Boix A, Goñi X, Castilla E, Pinedo M, Supersaxco L, Ferré M, Contreras J, Sanz-Manrique N, Lara A, Rodríguez M, Pineda T, Segura S, Vidal S, Salvat M, Mimbrero G, Albareda A, Guardia J, Gil S, Lopez M, Ruiz-Escusol S, Gallardo S, Machado P, Bocanegra R, Espejo T, Vendrell M, Solé C, Urbano R, Vázquez M, Fernández-Antuña L, Barrio M, Baudoin A, González N, Olivé R, Lara R, Dinu C, Vidal C, González S, Ruiz-Morcillo E, Ainsa M, Vilalta P, Aranda B, Boada A, Balcells E. Gut microbiota is associated with metabolic health in children with obesity. Clin Nutr 2022; 41:1680-1688. [DOI: 10.1016/j.clnu.2022.06.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 03/16/2022] [Accepted: 06/04/2022] [Indexed: 11/03/2022]
|
5
|
Goutaudier N, Martinelli N, Chevalère J, Dezecache G, Belletier C, Huguet P, Droit-Volet S, Gil S. Affective experiences during COVID-19 pandemic lockdown and posttraumatic growth: A 1-year longitudinal study in France. J Affect Disord 2022; 310:472-476. [PMID: 35577154 PMCID: PMC9101774 DOI: 10.1016/j.jad.2022.05.056] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 02/18/2022] [Accepted: 05/10/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND The COVID-19 crisis has resulted in major restrictions on daily life that are undeniably detrimental to individual wellbeing. Nevertheless, there may be positive psychological changes over the longer term, particularly in the form of posttraumatic growth (PTG). METHODS A total of 1075 individuals representative of the French population took part in an online survey during the first lockdown (T1: March to May 2020) and 1 year later (T2). Their affective experiences at T1 were analyzed, together with the development of PTG at T2. RESULTS Three affective profiles were identified at T1: one associated with feelings of loneliness and depressive symptoms (Loneliness cluster), one with positive feelings (Happiness cluster), and one with rather negative feelings of anger and fear, but also a feeling of happiness (Negative-moderate cluster). PTG was generally low at T2, with the Negative-moderate cluster achieving the highest score. LIMITATIONS This study was based on an online survey, and an exploratory cluster analysis was conducted. Complementary studies should be conducted to determine the predictive value of our findings. CONCLUSIONS Within the space of 1 year following the first lockdown due to COVID-19, people living in France, especially those who had experienced a mixture of feelings during lockdown, appeared to develop some form of PTG. Nevertheless, PTG was rather weak overall.
Collapse
Affiliation(s)
- N. Goutaudier
- Université de Poitiers; CNRS (CeRCA UMR7295), France,Corresponding author at: Centre de Recherches sur la Cognition et l'Apprentissage (CeRCA), Bât. A5, MSHS, 5 rue Théodore Lefebvre, TSA 21103, 86073 Poitiers Cedex 9, France
| | - N. Martinelli
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - J. Chevalère
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - G. Dezecache
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - C. Belletier
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - P. Huguet
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - S. Droit-Volet
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - S. Gil
- Université de Poitiers; CNRS (CeRCA UMR7295), France
| |
Collapse
|
6
|
Suárez-Vázquez S, Moreno-Román E, Zanella R, Cruz-López A, García-Goméz C, Nieto-Márquez A, Gil S. Insight into the surface reaction mechanism of toluene oxidation over a composite CeOx/La1-xCexMnO3 catalyst using Drifts. Chem Eng Sci 2022. [DOI: 10.1016/j.ces.2022.117831] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Benavides M, Alcaide-Garcia J, Torres E, Gil S, Durán G, Reyna C, Wolman R, Alvarez M, Kushnir M, Faull I, Muñoz M, Alba E. 503P Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Valladares-Ayerbes M, Toledano Fonseca M, Vieitez de Prado J, Inga-Saavedra E, Gil S, Graña Suarez B, García-Paredes B, Salud A, Rivera Herrero F, Salgado Fernandez M, García-Alfonso P, López-López R, Ferreiro Monteagudo R, Sastre J, Diaz-Rubio E, Aranda E. P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
9
|
Verdial C, Carneiro C, Machado I, Tavares L, Almeida V, Oliveira M, Gil S. Controlling bacteriological contamination of environmental surfaces at the biological isolation and containment unit of a veterinary teaching hospital. Ir Vet J 2021; 74:18. [PMID: 34183065 PMCID: PMC8240409 DOI: 10.1186/s13620-021-00197-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 06/15/2021] [Indexed: 11/23/2022] Open
Abstract
Background The Biological Isolation and Containment Unit (BICU) is a subunit of the Teaching Hospital of the Faculty of Veterinary Medicine of the University of Lisbon, Portugal, for the admission of animals with confirmed infectious diseases or under clinical suspicion and waiting for a diagnosis. As a high-risk environment for the transmission of infectious agents, it is extremely important to implement programs for the surveillance of nosocomial microorganisms in these facilities. The purpose of this study was to evaluate the level of bacterial contamination of the BICU environmental surfaces and to implement corrective actions on disinfection protocols. Swab samples were collected from selected environmental surfaces in 3 different areas of the BICU (isolation, work, and preparatory rooms) to evaluate the total aerobic bacterial load and investigate the presence of 4 nosocomial microorganisms: vancomycin-resistant Enterococcus spp., methicillin-resistant Staphylococcus aureus, 3rd-generation cephalosporin-resistant Escherichia coli, and carbapenem-resistant Pseudomonas aeruginosa. Bacterial quantification was performed by using non-selective media, while specific selective media were used for the isolation of the target microorganisms. Isolates were identified based on their macro and microscopic characteristics and their biochemical profile. Subsequently, new disinfection protocols were implemented, and their effectiveness evaluated. Results The surfaces with the highest bacterial load in the isolation, preparatory, and worker’s rooms were the cages, hand-held sponge, and telephone, respectively. Regarding the 4 pathogens investigated, Enterococcus spp. were the most frequently isolated (11.3%), followed by E. coli (1.5%) and P. aeruginosa (1.5%). One of the P. aeruginosa isolates obtained was resistant to imipenem. In the end, new disinfection protocols were implemented, which proved to be effective in reducing bacterial counts by 99.99% in cages and the sponge, and by 90 to 99% on the telephone. Conclusions This study allows to conclude that the cages and the human contact surfaces were the most contaminated in the isolation rooms. Nevertheless, the new disinfection strategies seemed to be effective in reducing environmental contamination, including by some potentially nosocomial agents, although more samples must be analyzed for definitive conclusions. These results may contribute to highlight the importance of infection prevention and control measures, as fundamental tools to reduce the spread of infectious agents in the hospital environment.
Collapse
Affiliation(s)
- C Verdial
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - C Carneiro
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - I Machado
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,Veterinary Teaching Hospital, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - L Tavares
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - V Almeida
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - M Oliveira
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - S Gil
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal. .,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal. .,Veterinary Teaching Hospital, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.
| |
Collapse
|
10
|
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO Open 2021; 6:100062. [PMID: 33711671 PMCID: PMC7970062 DOI: 10.1016/j.esmoop.2021.100062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/23/2020] [Accepted: 01/15/2021] [Indexed: 01/09/2023] Open
Abstract
Background We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). Patients and methods VISNÚ-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and <3 circulating tumour cells/7.5 ml blood were stratified by BRAF/PIK3CA status (wild-type versus mutated) and number of affected organs (1 versus >1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m2 then 250 mg/m2 weekly) plus FOLFIRI [irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 (bolus) then 2400 mg/m2 (46-h continuous infusion) every 2 weeks]. The primary endpoint was progression-free survival (PFS). All analyses were exploratory. Results Two hundred and forty patients with BRAF/PIK3CA wild-type (n = 196) or BRAF- and/or PIK3CA-mutated tumours (n = 44) were enrolled. Median PFS was 12.7 and 8.8 months in patients with BRAF/PIK3CA wild-type and BRAF/PIK3CA-mutated tumours, respectively [hazard ratio (HR) = 1.22; 95% confidence interval (CI) 0.80-1.85; P = 0.3602]. In the BRAF- and/or PIK3CA-mutated cohort, median PFS was 2.8, 8.8 and 15.0 months in patients with BRAF/PI3KCA-mutated (n = 8), BRAF-mutated/PI3KCA wild-type (n = 16) and BRAF wild-type/PI3KCA-mutated (n = 20) tumours, respectively (P = 0.0002). PFS was similar with bevacizumab plus FOLFIRI versus cetuximab plus FOLFIRI in BRAF/PIK3CA wild-type (HR = 0.99; 95% CI 0.67-1.45; P = 0.9486) and BRAF/PIK3CA-mutated tumours (HR = 1.11; 95% CI 0.53-2.35; P = 0.7820). The most common grade 3/4 treatment-related adverse events were neutropenia, diarrhoea and asthenia in both treatment groups. Conclusions BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy. This study examined if BRAF/PIK3CA mutational status can guide therapy in RAS wild-type mCRC. BRAF mutations were associated with poorer survival outcomes, and were potentiated by PI3KCA mutations. Bevacizumab-FOLFIRI versus cetuximab-FOLFIRI had similar outcomes in BRAF /PIK3CA wild-type and BRAF /PIK3CA-mutated tumours. BRAF and PI3KCA mutations have a role as prognostic but not predictive factors.
Collapse
Affiliation(s)
- J Sastre
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
| | - P García-Alfonso
- Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - J M Viéitez
- Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M T Cano
- Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain
| | - F Rivera
- Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - J J Reina-Zoilo
- Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Seville, Spain
| | - A Salud-Salvia
- Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
| | - G Quintero
- Medical Oncology, Hospital Lucus Augusti, Lugo, Spain
| | - L Robles-Díaz
- Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
| | - M J Safont
- Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain
| | - A La Casta
- Medical Oncology, Hospital de Donostia, Guipúzcoa, Spain
| | - S Gil
- Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Malaga, Spain
| | - E Polo
- Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain
| | - E Asensio-Martínez
- Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain
| | - B García-Paredes
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - R L López
- Medical Oncology, University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain
| | - M Guillot
- Medical Oncology, Hospital Son Espases, Palma de Mallorca, Spain
| | - M Valladares-Ayerbes
- Medical Oncology, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain
| | - E Aranda
- Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain
| | - E Díaz-Rubio
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | | |
Collapse
|
11
|
Kisteneff A, Gil S, O'Connell K, Edwards J, Lo B, Derber C. 335 HIV Post Exposure Prophylaxis in the Emergency Department: Barriers and Missed Opportunities. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Alves F, Prata S, Nunes T, Gomes J, Aguiar S, Aires da Silva F, Tavares L, Almeida V, Gil S. Canine parvovirus: a predicting canine model for sepsis. BMC Vet Res 2020; 16:199. [PMID: 32539830 PMCID: PMC7294767 DOI: 10.1186/s12917-020-02417-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 06/08/2020] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Sepsis is a severe condition associated with high prevalence and mortality rates. Parvovirus enteritis is a predisposing factor for sepsis, as it promotes intestinal bacterial translocation and severe immunosuppression. This makes dogs infected by parvovirus a suitable study population as far as sepsis is concerned. The main objective of the present study was to evaluate the differences between two sets of SIRS (Systemic Inflammatory Response Syndrome) criteria in outcome prediction: SIRS 1991 and SIRS 2001. The possibility of stratifying and classifying septic dogs was assessed using a proposed animal adapted PIRO (Predisposition, Infection, Response and Organ dysfunction) scoring system. RESULTS The 72 dogs enrolled in this study were scored for each of the PIRO elements, except for Infection, as all were considered to have the same infection score, and subjected to two sets of SIRS criteria, in order to measure their correlation with the outcome. Concerning SIRS criteria, it was found that the proposed alterations on SIRS 2001 (capillary refill time or mucous membrane colour alteration) were significantly associated with the outcome (OR = 4.09, p < 0.05), contrasting with the 1991 SIRS criteria (p = 0.352) that did not correlate with the outcome. No significant statistical association was found between Predisposition (p = 1), Response (p = 0.1135), Organ dysfunction (p = 0.1135), total PIRO score (p = 0.093) and outcome. To explore the possibility of using the SIRS criteria as a fast decision-making tool, a Fast-and-Frugal tree (FFT) was created with a sensitivity of 92% and a specificity of 29%. CONCLUSION These results suggest that increasing the SIRS criteria specificity may improve their prognostic value and their clinical usefulness. In order to improve the proposed PIRO scoring system outcome prediction ability, more specific criteria should be added, mainly inflammatory and organ dysfunction biomarkers.
Collapse
Affiliation(s)
- F. Alves
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - S. Prata
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - T. Nunes
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - J. Gomes
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - S. Aguiar
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - F. Aires da Silva
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - L. Tavares
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - V. Almeida
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - S. Gil
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| |
Collapse
|
13
|
Ruiz Ochoa A, Escudero Argaluza J, Alvarez Rodríguez B, Vasques Rocha M, Stoye C, Pompei Fernández O, Gil S, De Dios JR, Calvo-Alen J. FRI0434 PREDICTIVE FACTORS OF SERIOUS INFECTIONS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS ON TREATMENT WITH TNF INHIBITORS: REAL LIFE DATA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Serious infections are one of the most feared adverse events in patients treated with biologics. To this regard data coming from randomized and long-term extension studies may not totally applied to the usual clinical practice due to the different profile of the treated patients. To study the associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsObjectives:To study the associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods:All the medical records of the patients with inflammatory arthritis being treated with TNF inhibitors at the beginning of 2016 were retrospectively reviewed. All serious infections suffered for these patients until the end of 2018 were recorded. Serious infections were defined as those which required to admitted at the hospital for intravenous treatment. Potential variables associated with the development of these infections including: demographic and clinical characteristics, concomitant treatments or comorbidity (by Charlson index) were studied. Standard statistical tests for descriptive and univariate analyses were used and a multivariable logistic regression model was built to check independent associations.Results:Overall 334 patients (50.3% women) with a mean age of 56.67 (±12.853) were studied: 140 (41.92%) Rheumatoid arthritis (RA), 55 (16.46%) psoriatic arthritis (PsA) and 138 (41.62%) spondyloarthritis (Sp). Forty-five serious infections were observed in 30 patients, being respiratory (40%) and urinary (8.8%) the most frequent localizations. Only one patient died. By univariate analysis, disease duration, age, concomitan use of glucocorticoids (GC) (but not of synthetic DMARDs), Charlson index and specifically Diabetes Mellitus were associated with infection (p< 0.05). The type of arthritis was not associated and the results in the subset of RA patients were overall similar. In the multivariate analysis the use of GC [OR: 5.31 (1.98.14.26)] and the Charlson index [OR:2.48 (1.70;3.60)] were found to be independently associated to infection.Conclusion:In patients with inflammatory arthritis and treated with TNF inhibitors around a 10% developed any serious infection along three years of follow up. Use of GC and comorbidity emerged as the main risk factors for this complication.Disclosure of Interests:None declared
Collapse
|
14
|
de Rojas I, Romero J, Rodríguez-Gomez O, Pesini P, Sanabria A, Pérez-Cordon A, Abdelnour C, Hernández I, Rosende-Roca M, Mauleón A, Vargas L, Alegret M, Espinosa A, Ortega G, Gil S, Guitart M, Gailhajanet A, Santos-Santos MA, Moreno-Grau S, Sotolongo-Grau O, Ruiz S, Montrreal L, Martín E, Pelejà E, Lomeña F, Campos F, Vivas A, Gómez-Chiari M, Tejero MA, Giménez J, Pérez-Grijalba V, Marquié GM, Monté-Rubio G, Valero S, Orellana A, Tárraga L, Sarasa M, Ruiz A, Boada M. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res Ther 2018; 10:119. [PMID: 30497535 PMCID: PMC6267075 DOI: 10.1186/s13195-018-0444-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Accepted: 10/29/2018] [Indexed: 01/30/2023]
Abstract
BACKGROUND Peripheral biomarkers that identify individuals at risk of developing Alzheimer's disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results. METHODS The Fundació ACE Healthy Brain Initiative (FACEHBI) study uses a convenience sample of 200 individuals diagnosed with subjective cognitive decline (SCD) at the Fundació ACE (Barcelona, Spain) who underwent amyloid florbetaben(18F) (FBB) positron emission tomography (PET) brain imaging. Baseline plasma samples from FACEHBI subjects (aged 65.9 ± 7.2 years) were analyzed using the ABtest (Araclon Biotech). This test directly determines the free plasma (FP) and total plasma (TP) levels of Aβ40 and Aβ42 peptides. The association between Aβ40 and Aβ42 plasma levels and FBB-PET global standardized uptake value ratio (SUVR) was determined using correlations and linear regression-based methods. The effect of the APOE genotype on plasma Aβ levels and FBB-PET was also assessed. Finally, various models including different combinations of demographics, genetics, and Aβ plasma levels were constructed using logistic regression and area under the receiver operating characteristic curve (AUROC) analyses to evaluate their ability for discriminating which subjects presented brain amyloidosis. RESULTS FBB-PET global SUVR correlated weakly but significantly with Aβ42/40 plasma ratios. For TP42/40, this observation persisted after controlling for age and APOE ε4 allele carrier status (R2 = 0.193, p = 1.01E-09). The ROC curve demonstrated that plasma Aβ measurements are not superior to APOE and age in combination in predicting brain amyloidosis. It is noteworthy that using a simple preselection tool (the TP42/40 ratio with an empirical cut-off value of 0.08) optimizes the sensitivity and reduces the number of individuals subjected to Aβ FBB-PET scanners to 52.8%. No significant dependency was observed between APOE genotype and plasma Aβ measurements (p value for interaction = 0.105). CONCLUSION Brain and plasma Aβ levels are partially correlated in individuals diagnosed with SCD. Aβ plasma measurements, particularly the TP42/40 ratio, could generate a new recruitment strategy independent of the APOE genotype that would improve identification of SCD subjects with brain amyloidosis and reduce the rate of screening failures in preclinical AD studies. Independent replication of these findings is warranted.
Collapse
Affiliation(s)
- Itziar de Rojas
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | | | - O. Rodríguez-Gomez
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | | | - A. Sanabria
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Pérez-Cordon
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - C. Abdelnour
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - I. Hernández
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Rosende-Roca
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Mauleón
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - L. Vargas
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Alegret
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Espinosa
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - G. Ortega
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - S. Gil
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Guitart
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Gailhajanet
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. A. Santos-Santos
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - Sonia Moreno-Grau
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - O. Sotolongo-Grau
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - S. Ruiz
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - L. Montrreal
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - E. Martín
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - E. Pelejà
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - F. Lomeña
- Servei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain
| | - F. Campos
- Servei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain
| | - A. Vivas
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | - M. Gómez-Chiari
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | - M. A. Tejero
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | - J. Giménez
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | | | - G. M. Marquié
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - G. Monté-Rubio
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - S. Valero
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Orellana
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - L. Tárraga
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | | | - A. Ruiz
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Boada
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| |
Collapse
|
15
|
Nguyen T, Berrada-Gomez MP, Rielland A, Bellec M, Gil S, De Javel D, Ferret PJ. Usage patterns of cosmetic products by pregnant women. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Benavides M, Carrato A, Abad A, Guillen-Ponce C, Garcia-Alfonso P, Gil S, Cano Osuna M, Safont M, Gravalos C, Manzano-Mozo J, Sanchez A, Alcaide-Garcia J, López R, Massuti Sureda B, Sastre J, Martinez de Castro E, Escudero P, Méndez-Ureña M, Diaz Rubio E, Aranda Aguilar E. Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Sastre J, de la Orden V, Martínez A, Bando I, Santamaría I, Bellosillo Paricio B, Palanca S, Peligros I, Mediero B, Llovet P, Moreno V, Viéitez J, Garcia-Alfonso P, Gil S, Ortiz Morales M, Salud Salvia M, Quintero G, Gesto F, Aranda Aguilar E, Diaz Rubio E. Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Loturco I, Nakamura FY, Kobal R, Gil S, Pivetti B, Pereira LA, Roschel H. Traditional Periodization versus Optimum Training Load Applied to Soccer Players: Effects on Neuromuscular Abilities. Int J Sports Med 2016; 37:1051-1059. [PMID: 27706551 DOI: 10.1055/s-0042-107249] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
It is unknown whether traditional periodization of strength-power training involving accumulation, transformation and realization blocks is superior to other simpler and more practical training schemes. The purpose of this study was thus to investigate changes in strength/power/speed characteristics of elite soccer players in response to either classic strength-power periodization (TSP) or optimum power load (OPL). 23 professional soccer players were randomly assigned to TSP or OPL for 6 weeks in-season regular training (3 times per week). TSP involved half squats or jump squats, depending on the respective training block, while OPL involved only jump squats at the optimum power load. Results revealed that both groups presented similar significant (P<0.05) improvements in squat one repetition maximum, squat and countermovement jump heights and change of direction speed. In addition, although both groups reported significant increases in sprinting speed (P<0.05); delta change scores demonstrated a superior effect of OPL to improve 10- and 20-m speed. Similarly, OPL presented greater delta change in mean propulsive power in the jump squat. Therefore, training continuously at the optimum power zone resulted in superior performance improvements compared to training under classic strength-power periodization.
Collapse
Affiliation(s)
- I Loturco
- Sport Science, NAR - Nucleus of High Performance in Sport, São Paulo, Brazil
| | - F Y Nakamura
- Departamento de Educação Física, Universidade Estadual de Londrina, Londrina, Brazil
| | - R Kobal
- Department of Physical Education and Sport, University of São Paulo, São Paulo, Brazil
| | - S Gil
- NAR, Nucleus of High Performance in Sport, São Paulo, Brazil
| | - B Pivetti
- NAR - Nucleus of High Performance in Sport, NAR, São Paulo, Brazil
| | - L A Pereira
- Sport Science, NAR - Nucleus of High Performance in Sport, São Paulo, Brazil
| | - H Roschel
- Sport, University of Sao Paulo School of Physical Education and Sport, Sao Paulo, Brazil
| |
Collapse
|
19
|
Loturco I, Abad C, Nakamura FY, Ramos SP, Kobal R, Gil S, Pereira LA, Burini F, Roschel H, Ugrinowitsch C, Tricoli V. Effects of far infrared rays emitting clothing on recovery after an intense plyometric exercise bout applied to elite soccer players: a randomized double-blind placebo-controlled trial. Biol Sport 2016; 33:277-83. [PMID: 27601783 PMCID: PMC4993144 DOI: 10.5604/20831862.1208479] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2015] [Revised: 02/18/2016] [Accepted: 03/10/2016] [Indexed: 11/18/2022] Open
Abstract
The aim was to investigate the effects of far infrared (FIR) ray emitting clothes on indirect markers of exercise-induced muscle damage and physical performance recovery after a plyometric bout applied to soccer players. Twenty-one male players (18.9±0.6 years; 70.8±5.01 kg; 178.3±0.06 cm) performed 100 drop-jumps. Six hours after the bout, athletes put on FIR clothes (FIR) (density of 225 g·m-2, 88% far infrared rays emitting polyamide 66 Emana yarn (PA66) fibre, 12% Spandex, emissivity of 0.88 and power emitted of 341 W/m2µm at 37°C in the 5-20 µm wavelength range, patent WO 2009/077834 A2) (N = 10) or placebo clothes (PLA) (N = 11). Mid-thigh circumferences, creatine kinase (CK), and delayed-onset muscle soreness (DOMS) were assessed before, immediately after and 24, 48, and 72 h after the bout. Squat (SJ) and countermovement jump (CMJ) heights were measured before and at 24, 48, and 72 h after, while 1RM leg press (maximum strength) was measured before and at 72 h after the plyometrics. No differences between groups were found in mid-thigh circumferences, SJ, CMJ or 1RM. CK increased significantly 24 h after the plyometrics in comparison to before (p < 0.05) in both groups. PLA showed significant DOMS increases at 24, 48, and 72 h, while FIR showed significant increases at 24 and 48 h (p < 0.05). DOMS effect sizes were greater in FIR (moderate at 48 h, ES = 0.737 and large at 72 h, ES = 0.844), suggesting that FIR clothes may reduce perceived DOMS after an intense plyometric session performed by soccer players.
Collapse
Affiliation(s)
- I Loturco
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - Ccc Abad
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - F Y Nakamura
- State University of Londrina, Londrina, PR, Brazil
| | - S P Ramos
- State University of Londrina, Londrina, PR, Brazil
| | - R Kobal
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - S Gil
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - L A Pereira
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - Fhp Burini
- Nutrition and Exercise Metabolism Center - UNESP, Botucatu, SP, Brazil
| | - H Roschel
- School of Physical Education and Sport, University of São Paulo, São Paulo, SP, Brazil
| | - C Ugrinowitsch
- School of Physical Education and Sport, University of São Paulo, São Paulo, SP, Brazil
| | - V Tricoli
- School of Physical Education and Sport, University of São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
20
|
Gil S, Yébenes M, Luelmo J, Alsina M, Sabés M. A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: Potential chemotherapy alternative to surgery. Dermatol Ther 2016; 29:341-344. [PMID: 27292650 DOI: 10.1111/dth.12373] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Surgery as treatment for local invasive cutaneous squamous cell carcinoma (cSCC) is not always feasible due to the age and/or the health status of patients. Thus, the investigation of new strategies to improve the quality of life of them is required. The aim of this work is to investigate two chemotherapy agents individually on cSCC cells with the purpose to provide a better understanding of the effectiveness underlying each one. The cisplatin effectiveness is compared at different times with that observed for the 5-fluorouracil treatment. The effectiveness of both was assessed by using flow cytometry to determine the survival cell ratio, and QBlue test to study the cell recovery ability after treatments. A significant increase in the number of apoptotic cells, especially 48 hours after treatments, has been detected. Despite this, cisplatin arises as the most promising agent for the treatment of local invasive cutaneous squamous cell carcinoma due to the fact that a lower concentration and time are required to observe a higher effectiveness on cells with respect to the 5-fluorouracil. An optimal cisplatin-based chemotherapy might provide a better outcome for patients affected by a local invasive cSCC rather than surgery.
Collapse
Affiliation(s)
- S Gil
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain.
| | - M Yébenes
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain
| | - J Luelmo
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain
| | - M Alsina
- Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - M Sabés
- Department of Biophysics, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain
| |
Collapse
|
21
|
Abstract
In the present study, adults and children aged five and eight years were given a temporal bisection task involving emotional stimuli (angry and neutral faces) and three levels of discrimination difficulty that differed as a function of the ratio used between the short and the long standard duration (very easy, easy, and difficult). In addition, their cognitive capacities in terms of working memory and attention inhibition were assessed by neuropsychological tests. In the very easy temporal task (ratio of 1:4), the results showed that the psychophysical functions were shifted toward the left in all participants for the angry faces compared to the neutral faces, with a significant lowering of the Bisection Point, suggesting that the stimulus duration was judged to last longer for the emotional stimuli. In addition, the results did not show any relationship between the magnitude of this lengthening effect and individual cognitive capacities as assessed by the neuropsychological tests. The individual differences in working memory capacities only explained differences in sensitivity to time. However, when the difficulty of the temporal task increased, the children’s performance decreased and it was no longer possible to test for the emotional effect. Unlike the children, the adults were still able to discriminate time in the emotional task. However, the emotional effect was no longer observed. In conclusion, our study on temporal task difficulty shows the influence of available cognitive resources on the emergence of an emotional effect on time perception.
Collapse
Affiliation(s)
| | | | - S. Gil
- Université de Poitiers (CeRCA)France
| |
Collapse
|
22
|
Yousef I, Seksek O, Sulé-Suso J, Gil S, Prezado Y, Martínez-Rovira I. Infrared study of the biochemical effects in glioma cells induced by x-rays and Gd nanoparticles: first studies at SESAME synchrotron (Jordan). Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)30145-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Alvarado-Martínez E, Costero AM, Gil S, Peña-Cabrera E. Sensing and discrimination of cyanide and hydrogen sulfide using an 8-alkenyl-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene derivative. RSC Adv 2016. [DOI: 10.1039/c5ra23307k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
8-(2-Phenylethenyl)BODIPY has been shown to be an appropriate chromo-fluorogenic probe for cyanide in H2O.
Collapse
Affiliation(s)
| | - A. M. Costero
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico Universitat de València. Dr Moliner
- Valencia
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
- Spain
| | - S. Gil
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico Universitat de València. Dr Moliner
- Valencia
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
- Spain
| | - E. Peña-Cabrera
- Departamento de Química
- Universidad de Guanajuato. Col Noria Alta s/n
- Mexico
| |
Collapse
|
24
|
Muriel Lopez C, Perez-Ruiz E, Gonzalez I, Ales I, Pascual J, Duran G, Rivas-Ruiz F, Benavides M, Marquez A, Pajares B, Plata Y, Diaz T, Zarcos I, Alcaide J, Gimenez F, Lopez P, Gil S, Muros B, Rueda A, Alba E. 2304 Polychemotherapy on patients with pancreatic carcinoma: Experience of four hospitals in Spain. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31220-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Abstract
El ácaro Varroa destructor es el principal problema de sanidad animal al que se enfrenta nuestra apicultura. La cuantificación de la población de este ácaro es un factor de gran importancia para la inspección veterinaria y los apicultores, además determina la necesidad de realizar o no realizar tratamientos. En este trabajo se evalúan diferentes métodos de diagnóstico: i) ácaros desprendidos con azúcar en polvo o etanol del cuerpo de abejas adultas barridas de cuadros de alimento y cría, ii) ácaros obtenidos de celdillas de cría de abejas obreras y iii) ácaros caídos a los fondos de las colmenas en un período de 4 días. El número de ácaros recogidos de los fondos de las colonias presenta una correlación positiva con el número total de ácaros presentes en las colonias. La cuantificación del número de ácaros presentes en las abejas adultas o en la cría de obrera solo puede ser utilizada de forma indicativa para el diagnóstico. El uso del azúcar en polvo solo desprende un tercio de los ácaros presentes en el cuerpo de las obreras adultas.
Collapse
|
26
|
|
27
|
Quilis N, Gil S, Andrés M, Vela P, Pascual E. FRI0327 Febuxostat Appears Effective and Safe in Gout Patients with Severe Chronic Kidney Disease:. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3320] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Vela P, Abasolo L, Lajas C, Gil S, Cuenca N, Senabre J, Lopez A, Barros A, Macia C, Tejon P, Aparicio M, Rosas J, Perez T, Valdazo J, Medina J, Belmonte M, Nolla J, Jover J. AB1152 Early Intervention in Musculoskeletal Disease Can Reduce Temporary Work Disability. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Jovelet C, Seck A, Mir O, Simasotchi C, Broutin S, Goffinet F, Bidart JM, Paci A, Gil S. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Ann Oncol 2015; 26:1500-4. [PMID: 25851627 DOI: 10.1093/annonc/mdv172] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 03/25/2015] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The use of tyrosine kinase inhibitors (TKis) during pregnancy in humans remains rare, and little data are available on their transplacental passage. Erlotinib and gefitinib are the first-line targeted therapy in case of stage IV nonsmall-cell lung cancer with an EGFR-activating mutation. There are no data available regarding the comparative use of these TKis in pregnant patients. We aimed to compare the transplacental transfer of gefitinib, imatinib and erlotinib, using the ex vivo method of human perfused cotyledon, and to determine the placental accumulation of TKis. MATERIALS AND METHODS Term placentas were perfused after delivery with gefitinib, imatinib and erlotinib at targeted maternal concentrations around the steady-state plasma trough concentration (i.e. 500, 1000 and 1500 ng/ml, respectively). Samples from fetal and maternal circulations were collected in order to monitor TKis concentrations. Main transfer parameters such as fetal transfer rate (FTR), clearance index (CI) and placental uptake were assessed. RESULTS Mean FTR of gefitinib, imatinib and erlotinib were 16.8%, 10.6% and 31.4%, respectively. Mean CI of gefitinib, imatinib and erlotinib were 0.59, 0.48 and 0.93, respectively. Placental uptake in cotyledon was 0.030% %, 0.010% and 0.003% for gefitinib, imatinib and erlotinib, respectively, corresponding to a mean mass of 27.7 µg for gefitinib, 15.7 µg for imatinib and 6.8 µg for erlotinib. CONCLUSION The results suggest that TKis cross the placenta at therapeutic level. Particularly, erlotinib crosses the placenta at a higher rate than gefitinib or imatinib. All of them have a very low placental uptake. These data may suggest that gefitinib should be preferred to erlotinib for the treatment of pregnant woman with lung cancer harboring an EGFR-activating mutation, during the second and third trimesters of pregnancy.
Collapse
Affiliation(s)
- C Jovelet
- Translational Research Laboratory, Gustave Roussy, Villejuif
| | - A Seck
- Department of Pharmacology and Drug Analysis, Gustave Roussy, Villejuif
| | - O Mir
- Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif
| | | | - S Broutin
- Department of Pharmacology and Drug Analysis, Gustave Roussy, Villejuif
| | - F Goffinet
- PremUp Foundation, Paris Department of Gynaecology and Obstetrics, Teaching Hospital Cochin, Assistance Publique-Hôpitaux de Paris, DHU 'Risks in Pregnancy', University Paris Descartes, Paris
| | - J M Bidart
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif
| | - A Paci
- Department of Pharmacology and Drug Analysis, Gustave Roussy, Villejuif
| | - S Gil
- PremUp Foundation, Paris UMR-S 1139, INSERM, Paris Descartes University, Paris, France
| |
Collapse
|
30
|
Gil S, Weinberg M. Risk Factors for DSM 5 PTSD Symptoms in Israeli Civilians During the Gaza War. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)31188-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
31
|
Barbaux S, Erwich JJHM, Favaron PO, Gil S, Gallot D, Golos TG, Gonzalez-Bulnes A, Guibourdenche J, Heazell AEP, Jansson T, Laprévote O, Lewis RM, Miller RK, Monk D, Novakovic B, Oudejans C, Parast M, Peugnet P, Pfarrer C, Pinar H, Roberts CT, Robinson W, Saffery R, Salomon C, Sexton A, Staff AC, Suter M, Tarrade A, Wallace J, Vaillancourt C, Vaiman D, Worton SA, Lash GE. IFPA meeting 2014 workshop report: Animal models to study pregnancy pathologies; new approaches to study human placental exposure to xenobiotics; biomarkers of pregnancy pathologies; placental genetics and epigenetics; the placenta and stillbirth and fetal growth restriction. Placenta 2015; 36 Suppl 1:S5-10. [PMID: 25703592 DOI: 10.1016/j.placenta.2015.01.196] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/27/2015] [Indexed: 11/15/2022]
Abstract
Workshops are an important part of the IFPA annual meeting as they allow for discussion of specialized topics. At IFPA meeting 2014 there were six themed workshops, five of which are summarized in this report. These workshops related to various aspects of placental biology but collectively covered areas of animal models, xenobiotics, pathological biomarkers, genetics and epigenetics, and stillbirth and fetal growth restriction.
Collapse
Affiliation(s)
- S Barbaux
- Institut Cochin, INSERM U1016, Université Paris Descartes, Paris, France
| | - J J H M Erwich
- Department of Obstetrics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - P O Favaron
- School of Veterinary Medicine and Animal Science, University of São Paulo, Brazil
| | - S Gil
- Faculté de Pharmacie de Paris, Université Paris Descartes, Paris, France
| | - D Gallot
- CHU Clermont-Ferrand, Pôle Gynéco-Obstétrique-Reproduction Humaine, CHU Estaing, Clermont-Ferrand, France; Université d'Auvergne, Faculté de Médecine, Clermont-Ferrand, France
| | - T G Golos
- Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA; Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, USA
| | | | | | - A E P Heazell
- Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester, UK; St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - T Jansson
- Department of Obstetrics and Gynecology, University of Texas-San Antonio, San Antonio, TX, USA
| | - O Laprévote
- Faculté de Pharmacie de Paris, Université Paris Descartes, Paris, France
| | - R M Lewis
- Faculty of Medicine, University of Southampton, Southampton, UK
| | - R K Miller
- School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA
| | - D Monk
- Imprinting and Cancer Group, Cancer Epigenetic and Biology Program, Institut d'Investigació Biomedica de Bellvitge, Hospital Duran i Reynals, Barcelona, Spain
| | - B Novakovic
- Murdoch Childrens Research Institute, University of Melbourne, Melbourne, Australia
| | - C Oudejans
- VU University Medical Center, Amsterdam, The Netherlands
| | - M Parast
- Department of Pathology, Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, USA
| | - P Peugnet
- INRA, UMR1198 Developmental Biology and Reproduction, Jouy en Josas, France
| | - C Pfarrer
- Department of Anatomy, University of Veterinary Medicine Hannover, Germany
| | - H Pinar
- WIH, Division of Perinatal Pathology, Brown University, Providence, RI, USA
| | - C T Roberts
- Robinson Research Institute, University of Adelaide, Adelaide, Australia
| | - W Robinson
- Department of Medical Genetics, University of British Columbia, Canada; Child & Family Research Institute, Vancouver, British Columbia, Canada
| | - R Saffery
- Murdoch Childrens Research Institute, University of Melbourne, Melbourne, Australia
| | - C Salomon
- University of Queensland Centre for Clinical Research, Centre for Clinical Diagnostics, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - A Sexton
- Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), Seattle Children's, WA, USA
| | - A C Staff
- Department of Obstetrics and Gynecology, Oslo University Hospital and University of Oslo, Oslo, Norway
| | - M Suter
- Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
| | - A Tarrade
- INRA, UMR1198 Developmental Biology and Reproduction, Jouy en Josas, France; Fondation PremUp, Paris, France
| | - J Wallace
- Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK
| | - C Vaillancourt
- INRS-Institut Armand-Frappier and BioMed Research Center, Laval University, Québec, Canada
| | - D Vaiman
- AP-HP, INSERM - Université Paris Descartes, Paris, France
| | - S A Worton
- Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester, UK; St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - G E Lash
- Reproductive and Vascular Biology Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
| |
Collapse
|
32
|
Lavilla I, Valverde F, Gil S, Costas M, Pena F, Bendicho C. Determination of total lead and lead species according to their lability in coastal seawater by Chelex-100 titration and electrothermal-atomic absorption spectrometry. Chemical Speciation & Bioavailability 2015. [DOI: 10.3184/095422911x13200816298430] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Berveiller P, Degrelle S, Segond N, Cohen H, Evain-Brion D, Gil S. Drug transporter expression during in vitro differentiation of first-trimester and term human villous trophoblasts. Placenta 2015; 36:93-6. [DOI: 10.1016/j.placenta.2014.11.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 10/31/2014] [Accepted: 11/03/2014] [Indexed: 10/24/2022]
|
34
|
Ferri D, Barba-Bon A, Costero AM, Gaviña P, Parra M, Gil S. An Au(iii)–amino alcohol complex for degradation of organophosphorus pesticides. RSC Adv 2015. [DOI: 10.1039/c5ra20645f] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
A gold(iii)–amino alcohol complex induces the P–S bond cleavage in organophosphorous pesticides giving rise to less toxic compounds.
Collapse
Affiliation(s)
- D. Ferri
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico
- Universitat de València
- 46100-Burjassot
- Spain
| | - A. Barba-Bon
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico
- Universitat de València
- 46100-Burjassot
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
| | - A. M. Costero
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico
- Universitat de València
- 46100-Burjassot
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
| | - P. Gaviña
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico
- Universitat de València
- 46100-Burjassot
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
| | - M. Parra
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico
- Universitat de València
- 46100-Burjassot
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
| | - S. Gil
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico
- Universitat de València
- 46100-Burjassot
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
| |
Collapse
|
35
|
García E, Salazar MF, Gil S, Arizaga A. [Endotracheal tube cuff pressure and manometry]. Rev Esp Anestesiol Reanim 2014; 61:530. [PMID: 24411662 DOI: 10.1016/j.redar.2013.06.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Accepted: 06/20/2013] [Indexed: 06/03/2023]
Affiliation(s)
- E García
- Servicio de Anestesiología y Reanimación, Hospital Galdakao-Usansolo, Usansolo, Bizkaia, España.
| | - M F Salazar
- Servicio de Anestesiología y Reanimación, Hospital Galdakao-Usansolo, Usansolo, Bizkaia, España
| | - S Gil
- Servicio de Anestesiología y Reanimación, Hospital Galdakao-Usansolo, Usansolo, Bizkaia, España
| | - A Arizaga
- Servicio de Anestesiología y Reanimación, Hospital Galdakao-Usansolo, Usansolo, Bizkaia, España
| |
Collapse
|
36
|
Gil S, Goetgheluck J, Paci A, Broutin S, Friard S, Couderc L, Ayoubi J, Picone O, Tcherakian C. Efficacy and safety of gefitinib during pregnancy: Case report and literature review. Lung Cancer 2014; 85:481-4. [DOI: 10.1016/j.lungcan.2014.06.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Revised: 05/27/2014] [Accepted: 06/08/2014] [Indexed: 11/28/2022]
|
37
|
Abad C, do Nascimento A, Gil S, Kobal R, Loturco I, Nakamura F, Mostarda C, Irigoyen M. Cardiac Autonomic Control in High Level Brazilian Power and Endurance Track-and-Field Athletes. Int J Sports Med 2014; 35:772-8. [DOI: 10.1055/s-0033-1363268] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- C. Abad
- NAR – Nucleus of High Performance in Sport, São Paulo, Brazil
| | | | - S. Gil
- NAR – Nucleus of High Performance in Sport, São Paulo, Brazil
| | - R. Kobal
- NAR – Nucleus of High Performance in Sport, São Paulo, Brazil
| | - I. Loturco
- NAR – Nucleus of High Performance in Sport, São Paulo, Brazil
| | - F. Nakamura
- Departamento de Educação Física, Universidade Estadual de Londrina, Londrina, Brazil
| | - C. Mostarda
- Hospital Materno Infantil, Universidade Federal do Maranhão, São Luis, Brazil
| | | |
Collapse
|
38
|
Tarrade A, Lecarpentier E, Gil S, Morel O, Zahr N, Dahirel M, Tsatsaris V, Chavatte-Palmer P. Analysis of placental vascularization in a pharmacological rabbit model of IUGR induced by l-NAME, a nitric oxide synthase inhibitor. Placenta 2014; 35:254-9. [DOI: 10.1016/j.placenta.2014.01.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Revised: 01/28/2014] [Accepted: 01/29/2014] [Indexed: 11/25/2022]
|
39
|
Leal RO, Gil S, Sepúlveda N, McGahie D, Duarte A, Niza MMRE, Tavares L. Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-ω therapy. J Small Anim Pract 2013; 55:39-45. [PMID: 24279640 PMCID: PMC7166540 DOI: 10.1111/jsap.12160] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
OBJECTIVES Recombinant feline interferon-ω therapy is an immunomodulator currently used in the treatment of different retroviral diseases including feline immune deficiency virus and feline leukaemia virus. Although its mechanism of action remains unclear, this drug appears to potentiate the innate response. Acute phase proteins are one of the key components of innate immunity and studies describing their use as a monitoring tool for the immune system in animals undergoing interferon-ω therapy are lacking. This study aimed to determine whether interferon-ω therapy influences acute phase protein concentrations namely serum amyloid-A, α-1-glycoprotein and C-reactive protein. METHODS A single-arm study was performed using 16 cats, living in an animal shelter, naturally infected with retroviruses and subjected to the interferon-ω therapy licensed protocol. Samples were collected before (D0), during (D10 and D30) and after therapy (D65). Serum amyloid-A and C-reactive protein were measured by specific enzyme-linked immunosorbent assay kits and α-1-glycoprotein by single radial immunodiffusion. RESULTS All the acute phase proteins significantly increased in cats undergoing interferon-ω therapy (D0/D65: P<0·05) CLINICAL SIGNIFICANCE: Acute phase proteins appear to be reasonable predictors of innate-immune stimulation and may be useful in the individual monitoring of naturally retroviral infected cats undergoing interferon-ω therapy.
Collapse
Affiliation(s)
- R O Leal
- Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, Technical University of Lisbon (TULisbon), Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | | | | | | | | | | | | |
Collapse
|
40
|
Gil S, Leal RO, McGahie D, Sepúlveda N, Duarte A, Niza MMRE, Tavares L. Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation. Res Vet Sci 2013; 96:79-85. [PMID: 24332273 PMCID: PMC7111837 DOI: 10.1016/j.rvsc.2013.11.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2013] [Revised: 10/21/2013] [Accepted: 11/17/2013] [Indexed: 11/18/2022]
Abstract
Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP's variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol.
Collapse
Affiliation(s)
- S Gil
- Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal.
| | - R O Leal
- Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal
| | - D McGahie
- Virbac, 13(e) rue LID - BP 27, F 06511 Carros cedex, France
| | - N Sepúlveda
- London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, United Kingdom; Centro de Estatística e Aplicações da Universidade de Lisboa, FCUL, Bloco C6-Piso 4 Campo Grande, 1749 016 Lisboa, Portugal
| | - A Duarte
- Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal
| | - M M R E Niza
- Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal
| | - L Tavares
- Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal
| |
Collapse
|
41
|
Corbel T, Gayrard V, Berrebi A, Gil S, Lacroix M, Puel S, Viguié C, Toutain P, Picard-Hagen N. Bidirectional placental transfer of BPA and its metabolite in the perfused human placental cotyledon model. Toxicol Lett 2013. [DOI: 10.1016/j.toxlet.2013.05.505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
del Olmo L, Aguado P, Coya J, Lojo L, Nuño L, Gil S, Martín Mola E, Balsa A. THU0064 Comparison of estimated fracture risk using the FRAX index calculated with and without bone densitometry in patients with early arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Saad H, Khalil E, Bora SA, Parikh J, Abdalla H, Thum MY, Bina V, Roopa P, Shyamala S, Anupama A, Tournaye H, Polyzos NP, Guzman L, Nelson SM, Lourenco B, Sousa AP, Almeida-Santos T, Ramalho-Santos J, Okhowat J, Wirleitner B, Neyer T, Bach M, Murtinger M, Zech NH, Polyzos NP, Nwoye M, Corona R, Blockeel C, Stoop D, Camus M, Tournaye H, Rajikin MH, Kamsani YS, Chatterjee A, Nor-Ashikin MNK, Nuraliza AS, Scaravelli G, D'Aloja P, Bolli S, De Luca R, Spoletini R, Fiaccavento S, Speziale L, Vigiliano V, Farquhar C, Brown J, Arroll N, Gupta D, Boothroyd C, Al Bassam M, Moir J, Johnson N, Pantasri T, Robker RL, Wu LL, Norman RJ, Buzaglo K, Velez M, Shaulov T, Sylvestre C, Kadoch IJ, Krog M, Prior M, Carlsen E, Loft A, Pinborg A, Andersen AN, Dolleman M, Verschuren WMM, Eijkemans MJC, Dolle MET, Jansen EHJM, Broekmans FJM, Van der Schouw YT, Fainaru O, Pencovich N, Hantisteanu S, Barzilay I, Ellenbogen A, Hallak M, Cavagna M, Baruffi RLR, Petersen CG, Mauri AL, Massaro FC, Ricci J, Nascimento AM, Vagnini LD, Pontes A, Oliveira JBA, Franco JG, Canas MCT, Vagnini LD, Nascimento AM, Petersen CG, Mauri AL, Massaro FC, Nicoletti A, Martins AMVC, Cavagna M, Oliveira JBA, Baruffi RLR, Franco JG, Lichtblau I, Olivennes F, Aubriot FA, Junca AM, Belloc S, Cohen-Bacrie M, Cohen-Bacrie P, de Mouzon J, Nandy T, Caragia A, Balestrini S, Zosmer A, Sabatini L, Al-Shawaf T, Seshadri S, Khalaf Y, Sunkara SK, Joy J, Lambe M, Lutton D, Nicopoullos J, Bora SA, Parikh J, Faris R, Abdalla H, Thum MY, Behre HM, Howles CM, Longobardi S, Chimote N, Mehta B, Nath N, Chimote NM, Mehta B, Nath N, Chimote N, Chimote NM, Mine K, Yoshida A, Yonezawa M, Ono S, Abe T, Ichikawa T, Tomiyama R, Nishi Y, Kuwabara Y, Akira S, Takeshita T, Shin H, Song HS, Lim HJ, Hauzman E, Kohls G, Barrio A, Martinez-Salazar J, Iglesias C, Velasco JAG, Tejada MI, Maortua H, Mendoza R, Prieto B, Martinez-Bouzas C, Diez-Zapirain M, Martinez-Zilloniz N, Matorras R, Amaro A, Bianco B, Christofolini J, Mafra FA, Barbosa CP, Christofolini DM, Pesce R, Gogorza S, Ochoa C, Gil S, Saavedra A, Ciarmatori S, Perman G, Pagliardini L, Papaleo E, Corti L, Vanni VS, Ottolina J, de Michele F, Marca AL, Vigano P, Candiani M, Li L, Yin Q, Huang L, Huang J, He Z, Yang D, Parikh J, Bora SA, Abdalla H, Thum MY, Tiplady S, Ledger W, Godbert S, Hart S, Johnson S, Wong AWY, Kong GWS, Haines CJ, Franik S, Nelen W, Kremer J, Farquhar C, Gillett WR, Lamont JM, Peek JC, Herbison GP, Sung NY, Hwang YI, Choi MH, Song IO, Kang IS, Koong MK, Lee JS, Yang KM, Celtemen MB, Telli P, Karakaya C, Bozkurt N, Gursoy RH, Younis JS, Ben-Ami M, Pundir J, Pundir V, Omanwa K, Khalaf Y, El-Toukhy T. Female (in)fertility. Hum Reprod 2013. [DOI: 10.1093/humrep/det213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Gil S, del Olmo L, García S, Alcocer P, Lojo L, Plasencia C, Bonilla M, Balsa A, Martin-Mola E. AB0434 Association between cardiovascular events and classic cardiovascular risk factors and disease characteristics in patients with rheumatoid arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
del Olmo L, Acín P, Nuño L, Coya J, Oliveira L, Balsa A, Gil S, Martin Mola E. AB0394 Cardiovascular risk factors and their association with bone metabolism and disease activity in patients with early arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L, Garcia-Marcilla A, Gil S, Lopez-Rubio M, Martin E, Muñoz C, Ricard P, Soto C, Balsalobre P, Villegas A. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 2012; 92:19-24. [DOI: 10.1007/s00277-012-1565-4] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Accepted: 08/21/2012] [Indexed: 10/27/2022]
|
47
|
Duarte A, Faísca P, Loureiro NS, Rosado R, Gil S, Pereira N, Tavares L. First histological and virological report of fibropapilloma associated with herpesvirus in Chelonia mydas at Príncipe Island, West Africa. Arch Virol 2012; 157:1155-9. [DOI: 10.1007/s00705-012-1285-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Accepted: 02/13/2012] [Indexed: 10/28/2022]
|
48
|
Nugier A, Gil S, Chekroun P. Validation française du test des émotions réflexives (French-TOSCA-3) : une mesure des tendances émotionnelles de honte et de culpabilité. European Review of Applied Psychology 2012. [DOI: 10.1016/j.erap.2011.09.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
49
|
Thervet E, Gil S, Croux L, Zahr N, Jobart M, Legendre C, Lott MC, Benachi A. Étude ex vivo du transfert transplacentaire du tacrolimus chez des receveurs d’une transplantation rénale. Nephrol Ther 2011. [DOI: 10.1016/j.nephro.2011.07.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Cabaleiro N, De La Calle I, Gil S, Pena FJ, Costas M, Bendicho C, Lavilla I. Simultaneous ultrasound-assisted emulsification-derivatization as a simple and miniaturized sample preparation method for determination of nitrite in cosmetic samples by microvolume UV-vis spectrophotomety. Talanta 2010; 83:386-90. [PMID: 21111150 DOI: 10.1016/j.talanta.2010.09.053] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Revised: 09/13/2010] [Accepted: 09/25/2010] [Indexed: 10/19/2022]
Abstract
A simple and miniaturized approach based on ultrasound-assisted emulsification-derivatization is proposed for the determination of nitrite in cosmetic samples by UV-vis micro-spectrophotometry. Oil/water emulsions were formed using 15 mg of cosmetic sample and 1 mL of an aqueous medium containing 0.5% w/v SDS and 1% v/v acetic acid. When powerful sonication systems were used to make emulsions, i.e. probe or cup-horn sonoreactor, stable and transparent emulsions were obtained in one or half minute per sample, respectively. The Griess reaction in these special conditions (i.e. sonication and the presence of an organized medium) was investigated. The absence of matrix effects allows external calibration with aqueous standards for nitrite quantification. Analytical features were compared to those of the European official method 82/434/EEC. Detection limit, sample throughput and reagent consumption were significantly improved.
Collapse
Affiliation(s)
- N Cabaleiro
- Departamento de Química Analítica y Alimentaria, Área de Química Analítica, Facultad de Química, Universidad de Vigo, As Lagoas-Marcosende s/n, 36310 Vigo, Spain
| | | | | | | | | | | | | |
Collapse
|